Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PXS1100
- Development stage
- Unknown
- Lead developer
- Syntara
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PXS1100 is an investigational small molecule drug developed by Pharmaxis. It is a selective inhibitor of the chemokine receptor CXCR4. The primary mechanism of action involves antagonism of CXCR4, which plays a key role in the migration and retention of hematopoietic stem cells and leukocytes in bone marrow and tissues. By inhibiting CXCR4, PXS1100 mobilizes stem cells into peripheral blood, making it potentially useful for stem cell transplantation procedures as well as for diseases where abnormal cell trafficking contributes to pathology, such as certain cancers and fibrotic disorders. Pharmaxis has reported preclinical data supporting its use in these indications.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on PXS1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PXS1100.